Skip to content

The changes and significances of sFlt-1 and VEGF in children with Henoch-Schonlein purpura and Henoch-Schonlein purpura nephritis

The changes and significances of sFlt-1 and VEGF in children with Henoch-Schonlein purpura and Henoch-Schonlein purpura nephritis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023662
Enrollment
Unknown
Registered
2019-06-05
Start date
2019-07-01
Completion date
Unknown
Last updated
2019-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Henoch-Schonlein purpura and Henoch-Sch?nlein purpura nephritis

Interventions

Normal control group
HSP group
HSPN group:none

Sponsors

The First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 18 Years

Inclusion criteria

Inclusion criteria: HSP group: (1) has a typical history of Henoch-Schonlein purpura haptic rash, in line with the HSP diagnostic criteria developed by the Immunology Group of the Chinese Medical Association Pediatrics in 2013; (2) Aged = 18 years. HSPN group: (1) has a typical history of allergic purpura, in line with the HSPN diagnostic criteria developed by the Nephrology Group of the Chinese Medical Association Pediatrics in 2016: hematuria and/or proteinuria within 6 months of HSP disease; renal pathology Mesangial proliferative glomerulonephritis, which is mainly deposited in the IgA mesangial area, is shown. (2) Aged = 18 years.

Exclusion criteria

Exclusion criteria: (1) systemic lupus erythematosus; (2) primary IgA nephropathy, hepatitis B virus-associated nephropathy, lupus nephritis, thin basement membrane nephropathy and other kidney diseases; (3) those who have been treated with glucocorticoids and/or immunosuppressive agents for the past 4 weeks; (4) have tumors, trauma, serious infections, cardiovascular diseases and other autoimmune diseases.

Design outcomes

Primary

MeasureTime frame
sFlt-1;VEGF;

Countries

China

Contacts

Public ContactZhang Jianjiang

The First Affiliated Hospital of Zhengzhou University

zhangjianjiang10@163.com+86 15936269856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026